Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 23

Sort by

Sort Order Select

Meeting Abstracts

1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58

YU MI KANG, GIORGIO E.M. MELLONI, AVIVIT CAHN, ITAMAR RAZ, FILIPE MOURA, DEEPAK L. BHATT, SILVIO E. INZUCCHI, LAWRENCE A. LEITER, DARREN K. MCGUIRE, JOHN WILDING, INGRID A. GAUSE-NILSSON, JAN OSCARSSON, NICHOLAS MARSTON, CHRISTIAN T. RUFF, MARC S. SABATINE, STEPHEN D. WIVIOTT

Diabetes 2024;73(Supplement_1):1896-LB

https://doi.org/10.2337/db24-1896-LB

Published: 14 June 2024

View article titled, 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58

Meeting Abstracts

1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58

Diabetes 2024;73(Supplement_1):1895-LB

https://doi.org/10.2337/db24-1895-LB

Published: 14 June 2024

View article titled, 1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58

Meeting Abstracts

864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED

Diabetes 2022;71(Supplement_1):864-P

https://doi.org/10.2337/db22-864-P

Published: 01 June 2022

View article titled, 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED

Meeting Abstracts

445-P: CV Risk Factor Control in Patients with T2D and Coronary Artery Disease vs. Stroke

PRIYADARSHINI BALASUBRAMANIAN, WALTER KERNAN, KEVIN N. SHETH, ANNE PERNILLE OFSTAD, MICHAELA MATTHEUS, NIKOLAUS MARX, SILVIO E. INZUCCHI

Diabetes 2022;71(Supplement_1):445-P

https://doi.org/10.2337/db22-445-P

Published: 01 June 2022

View article titled, 445-P: CV Risk Factor Control in Patients with T2D and Coronary Artery Disease vs. Stroke

Journal Articles

Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

Emil Wolsk, Mikkel Jürgens, Morten Schou, Mads Ersbøll, Philip Hasbak, Andreas Kjær, Bo Zerahn, Niels Høgh Brandt, Peter Haulund Gæde, Peter Rossing, Jens Faber, Silvio E. Inzucchi, Caroline Michaela Kistorp, Finn Gustafsson

Diabetes 2022;71(4):812–820

https://doi.org/10.2337/db21-0721

Published: 21 January 2022

View article titled, Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

Meeting Abstracts

790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME

SILVIO E. INZUCCHI, CHRISTOPH WANNER, DAVID H. FITCHETT, BERNARD ZINMAN, STEFAN ANKER, MICHAELA MATTHEUS, OLA VEDIN, STEFAN HANTEL, SØREN S. LUND

Diabetes 2021;70(Supplement_1):790-P

https://doi.org/10.2337/db21-790-P

Published: 01 June 2021

View article titled, 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME

Meeting Abstracts

319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial

SABINE KAHL, ANNE PERNILLE OFSTAD, BERNARD ZINMAN, CHRISTOPH WANNER, ELKE SCHUELER, SILVIO E. INZUCCHI, MICHAEL RODEN

Diabetes 2021;70(Supplement_1):319-OR

https://doi.org/10.2337/db21-319-OR

Published: 01 June 2021

View article titled, 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial

Meeting Abstracts

873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia

DIANA ATHONVARANGKUL, LEIGH B. BAK, CINDY ZHENG, JULIE D’AMBROSI, JONATHAN SINER, SHYOKO HONIDEN, SILVIO E. INZUCCHI

Diabetes 2021;70(Supplement_1):873-P

https://doi.org/10.2337/db21-873-P

Published: 01 June 2021

View article titled, 873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia

Meeting Abstracts

30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

MUTHIAH VADUGANATHAN, NAVEED SATTAR, DAVID H. FITCHETT, ANNE PERNILLE OFSTAD, MARTINA BRUECKMANN, JYOTHIS T. GEORGE, SUBODH VERMA, MICHAELA MATTHEUS, CHRISTOPH WANNER, SILVIO E. INZUCCHI, BERNARD ZINMAN, JAVED BUTLER

Diabetes 2020;69(Supplement_1):30-OR

https://doi.org/10.2337/db20-30-OR

Published: 01 June 2020

View article titled, 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

Meeting Abstracts

380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM)

KASIA J. LIPSKA, MARGARET M. DOYLE, EDA CENGIZ, BONNIE DROZDOWICZ, THOMAS M. GILL, TERRENCE E. MURPHY, SILVIO E. INZUCCHI

Diabetes 2020;69(Supplement_1):380-P

https://doi.org/10.2337/db20-380-P

Published: 01 June 2020

View article titled, 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM)

Meeting Abstracts

927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4

RICHARD E. PRATLEY, ROBERT BAUER, SILVIO E. INZUCCHI, KAMLESH KHUNTI, ESKIL B. KREINER, PETER N. LAURSEN, JURIS J. MEIER

Diabetes 2020;69(Supplement_1):927-P

https://doi.org/10.2337/db20-927-P

Published: 01 June 2020

View article titled, 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4

Meeting Abstracts

271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF

Diabetes 2020;69(Supplement_1):271-OR

https://doi.org/10.2337/db20-271-OR

Published: 01 June 2020

View article titled, 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF

Meeting Abstracts

28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

SUBODH VERMA, LAWRENCE A. LEITER, ABHINAV SHARMA, BERNARD ZINMAN, MICHAELA MATTHEUS, DAVID H. FITCHETT, JYOTHIS T. GEORGE, ANNE PERNILLE OFSTAD, CHRISTOPH WANNER, SILVIO E. INZUCCHI

Diabetes 2020;69(Supplement_1):28-OR

https://doi.org/10.2337/db20-28-OR

Published: 01 June 2020

View article titled, 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

Meeting Abstracts

23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center

LEIGH B. BAK, THOMAS M. FANDEL, JANIS E. BOZZO, MICHELLE L. DEWITT, PING CHEN, RICHARD A. PANDO, LINDA FERRO, RORY KAPLAN, KARRIE C. HENDRICKSON, STEPHANIE B. AMPORT, L. SCOTT SUSSMAN, SILVIO E. INZUCCHI

Diabetes 2020;69(Supplement_1):23-OR

https://doi.org/10.2337/db20-23-OR

Published: 01 June 2020

View article titled, 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center

Meeting Abstracts

131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

SILVIO E. INZUCCHI, BERNARD ZINMAN, CHRISTOPH WANNER, DAVID H. FITCHETT, STEFAN ANKER, STUART POCOCK, STEFAN KASPERS, JYOTHIS T. GEORGE, ODD ERIK JOHANSEN, WAHEED JAMAL, STEFAN HANTEL, SØREN S. LUND

Diabetes 2020;69(Supplement_1):131-LB

https://doi.org/10.2337/db20-131-LB

Published: 01 June 2020

View article titled, 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

Meeting Abstracts

132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects

SILVIO E. INZUCCHI, BETTINA J. KRAUS, MATTHEW R. WEIR, GEORGE BAKRIS, MICHAELA MATTHEUS, DAVID CHERNEY, NAVEED SATTAR, HIDDO L. HEERSPINK, IVANA RITTER, MAXIMILIAN VON EYNATTEN, BERNARD ZINMAN, CHRISTOPH WANNER, AUDREY KOITKA-WEBER

Diabetes 2020;69(Supplement_1):132-LB

https://doi.org/10.2337/db20-132-LB

Published: 01 June 2020

View article titled, 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects

Meeting Abstracts

1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial

IAN J. NEELAND, BJORN ELIASSON, TAKATOSHI KASAI, NIKOLAUS MARX, BERNARD ZINMAN, SILVIO E. INZUCCHI, CHRISTOPH WANNER, ISABELLA ZWIENER, BRIAN S. WOJECK, HENRY K. YAGGI, ODD ERIK JOHANSEN

Diabetes 2020;69(Supplement_1):1128-P

https://doi.org/10.2337/db20-1128-P

Published: 01 June 2020

View article titled, 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial

Meeting Abstracts

1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial

KIERAN DOCHERTY, SILVIO E. INZUCCHI, MIKHAIL N. KOSIBOROD, LARS KOBER, ANNA MARIA LANGKILDE, FELIPE MARTINEZ, OLOF BENGTSSON, DAVID L. DEMETS, MIKAELA SJÖSTRAND, MARC S. SABATINE, SCOTT SOLOMON, PARDEEP JHUND, JOHN J. MCMURRAY

Diabetes 2020;69(Supplement_1):1112-P

https://doi.org/10.2337/db20-1112-P

Published: 01 June 2020

View article titled, 1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial

Meeting Abstracts

159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME

BERNARD ZINMAN, DAVID H. FITCHETT, MICHAELA MATTHEUS, CHRISTOPH WANNER, JYOTHIS T. GEORGE, OLA VEDIN, SILVIO E. INZUCCHI, ODD ERIK JOHANSEN

Diabetes 2019;68(Supplement_1):159-LB

https://doi.org/10.2337/db19-159-LB

Published: 01 June 2019

View article titled, 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME

Meeting Abstracts

19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME

SILVIO E. INZUCCHI, KAMLESH KHUNTI, DAVID H. FITCHETT, CHRISTOPH WANNER, MICHAELA MATTHEUS, JYOTHIS GEORGE, ANNE PERNILLE OFSTAD, BERNARD ZINMAN

Diabetes 2019;68(Supplement_1):19-LB

https://doi.org/10.2337/db19-19-LB

Published: 01 June 2019

View article titled, 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME

NARROW

1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58

1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58

864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED

445-P: CV Risk Factor Control in Patients with T2D and Coronary Artery Disease vs. Stroke

Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME

319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial

873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia

30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM)

927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4

271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF

28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center

131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects

1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial

1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial

159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME

19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only